Page last updated: 2024-12-10
t-muurolol
Description
T-muurolol: antifungal from Calocedrus formosana leaf; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
(-)-Tau-muurolol : A cadinane sesquiterpenoid that consists of 4-isopropyl-1,6-dimethyl-1,2,3,4,4a,7,8,8a-octahydronaphthalene having a hydroxy substituent at position 1 and (1S,4S,4aR,8aS)-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|
| Calocedrus | genus | [no description available] | Cupressaceae | A plant family of the order Pinales, class Pinopsida, division Tracheophyta. They are mainly resinous, aromatic evergreen trees.[MeSH] |
| Calocedrus formosana | species | [no description available] | Cupressaceae | A plant family of the order Pinales, class Pinopsida, division Tracheophyta. They are mainly resinous, aromatic evergreen trees.[MeSH] |
Cross-References
Synonyms (21)
| Synonym |
|---|
| 1-naphthalenol, 1,2,3,4,4a,7,8,8a-octahydro-1,6-dimethyl-4-(1-methylethyl)-, (1s-(1alpha,4alpha,4aalpha,8aalpha))- |
| epi-alpha-muurolol |
| (1s,4s,4ar,8as)-4-isopropyl-1,6-dimethyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-ol |
| alpha-epi-muurolol |
| (-)-tau-muurolol |
| 10-epi-alpha-muurolol |
| t-muurolol |
| CHEBI:132906 |
| 19912-62-0 |
| (1s,4s,4ar,8as)-1,6-dimethyl-4-propan-2-yl-3,4,4a,7,8,8a-hexahydro-2h-naphthalen-1-ol |
| CHEMBL2228956 |
| SCHEMBL5653479 |
| .alpha.-epi-muurolol |
| epi-.alpha.-muurolol |
| LHYHMMRYTDARSZ-AJNGGQMLSA-N |
| t-muuroloi |
| 4-isopropyl-1,6-dimethyl-1,2,3,4,4a,7,8,8a-octahydro-1-naphthalenol-, [1s-(1.alpha.,4.alpha.,4a.alpha.,8a.alpha.)]- |
| (-)-t-muurolol |
| muurolol t |
| DTXSID10173698 |
| Q63409422 |
Roles (5)
| Role | Description |
|---|
| plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
| fungicide | A substance used to destroy fungal pests. |
| volatile oil component | Any plant metabolite that is found naturally as a component of a volatile oil. |
| marine metabolite | Any metabolite produced during a metabolic reaction in marine macro- and microorganisms. |
| bacterial metabolite | Any prokaryotic metabolite produced during a metabolic reaction in bacteria. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (4)
| Class | Description |
|---|
| cadinane sesquiterpenoid | Any sesquiterpenoid with a cadinane skeleton. |
| carbobicyclic compound | A bicyclic compound in which all the ring atoms are carbon. |
| tertiary alcohol | A tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it. |
| octahydronaphthalenes | Any carbobycyclic compound that is an octahydronaphthalene or a compound obtained from an octahydronaphthalene by formal substitution of one or more hydrogens. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID1082713 | Antifungal activity against Laetiporus sulphureus BCRC 35305 (wood decay fungi) assessed as reduction of fungi mycelium growth at 100 ug/ml | 2012 | Journal of agricultural and food chemistry, Jan-11, Volume: 60, Issue:1
| Phytochemicals from Cunninghamia konishii Hayata act as antifungal agents. |
| AID1082714 | Antifungal activity against Trametes versicolor BCRC 35253 wood decay fungi assessed as reduction of fungi mycelium growth at 100 ug/ml | 2012 | Journal of agricultural and food chemistry, Jan-11, Volume: 60, Issue:1
| Phytochemicals from Cunninghamia konishii Hayata act as antifungal agents. |
| AID1082715 | Antifungal activity against Lenzites betulinus BCRC 35296 assessed as reduction of fungi mycelium growth at 100 ug/ml | 2012 | Journal of agricultural and food chemistry, Jan-11, Volume: 60, Issue:1
| Phytochemicals from Cunninghamia konishii Hayata act as antifungal agents. |
| AID1082712 | Antifungal activity against Gloeophyllum trabeum BCRC 31614 (wood decay fungi) assessed as reduction of fungi mycelium growth at 100 ug/ml | 2012 | Journal of agricultural and food chemistry, Jan-11, Volume: 60, Issue:1
| Phytochemicals from Cunninghamia konishii Hayata act as antifungal agents. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 24.89
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 24.89 (24.57) | | Research Supply Index | 2.08 (2.92) | | Research Growth Index | 5.33 (4.65) | | Search Engine Demand Index | 23.28 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |